We are live on
!
Find out more
CS
Candriam SCA Portfolio holdings
AUM
$19.3B
1-Year Est. Return
39.18%
This Fund
S&P 500
This Quarter
Est. Return
+29.29%
1 Year Est. Return
+39.18%
3 Year Est. Return
+109.85%
5 Year Est. Return
+149.31%
10 Year Est. Return
+617.16%
AUM
$9.47B
AUM Growth
+$451M
(+5%)
Cap. Flow
+$1.13B
Cap. Flow
% of AUM
11.96%
Top 10 Holdings %
Top 10 Hldgs %
21.59%
Holding
903
New
107
Increased
255
Reduced
393
Closed
103
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
BPMC
Blueprint Medicines
BPMC
|
+$51.9M |
| 2 |
Merck
MRK
|
+$50.9M |
| 3 |
Danaher
DHR
|
+$45.3M |
| 4 |
Thermo Fisher Scientific
TMO
|
+$37.8M |
| 5 |
JD.com
JD
|
+$37.7M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Regeneron Pharmaceuticals
REGN
|
+$103M |
| 2 |
Alibaba
BABA
|
+$98.6M |
| 3 |
Salesforce
CRM
|
+$62.5M |
| 4 |
Bristol-Myers Squibb
BMY
|
+$59.4M |
| 5 |
Vertex Pharmaceuticals
VRTX
|
+$48.6M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 34.61% |
| 2 | Technology | 20.94% |
| 3 | Consumer Discretionary | 8.9% |
| 4 | Financials | 8.59% |
| 5 | Communication Services | 7.45% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
601
Invitation Homes
INVH
$17.9B
| $823K | 0.01% |
29,909
-15,850
| -35% | -$397K |
|
602
Beyond Meat
BYND
$279M
| $820K | 0.01% |
+6,121
| New | +$725K |
|
603
Keurig Dr Pepper
KDP
$42.3B
| $814K | 0.01% |
+28,648
| New | +$777K |
|
604
Expedia Group
EXPE
$35.5B
| $813K | 0.01% |
9,894
-21,952
| -69% | -$1.6M |
|
605
International Flavors & Fragrances
IFF
$20.2B
| $812K | 0.01% |
6,634
-3,545
| -35% | -$448K |
|
606
Liberty Broadband Class C
LBRDK
$4.72B
| $810K | 0.01% |
+6,531
| New | +$820K |
|
607
Las Vegas Sands
LVS
$32B
| $810K | 0.01% |
17,785
-8,462
| -32% | -$398K |
|
608
Supernus Pharmaceuticals
SUPN
$2.77B
| $808K | 0.01% |
34,000
-159,000
| -82% | -$3.51M |
|
609
Gildan
GIL
$9.58B
| $800K | 0.01% |
+51,804
| New | +$765K |
|
610
Genuine Parts
GPC
$17.9B
| $798K | 0.01% |
9,172
-4,849
| -35% | -$383K |
|
611
Western Digital
WDC
$160B
| $798K | 0.01% |
23,915
-13,464
| -36% | -$436K |
|
612
Artivion
AORT
$1.31B
| $794K | 0.01% |
41,403
-3,597
| -8% | -$76.3K |
|
613
Loop Industries
LOOP
$35.6M
| $792K | 0.01% |
+88,025
| New | +$756K |
|
614
Canadian Imperial Bank of Commerce
CM
$109B
| $791K | 0.01% |
23,750
-38,308
| -62% | -$1.2M |
|
615
Itaú Unibanco
ITUB
$91.6B
| $789K | 0.01% |
231,153
-86,644
| -27% | -$281K |
|
616
Wayfair
W
$12.5B
| $783K | 0.01% |
+3,963
| New | +$593K |
|
617
Fox Class B
FOX
$21.7B
| $771K | 0.01% |
28,735
+1,857
| +7% | +$49.4K |
|
|
ABMD
618
DELISTED
Abiomed Inc
ABMD
| $771K | 0.01% |
3,191
-561
| -15% | -$113K |
|
619
Mitsubishi UFJ Financial
MUFG
$253B
| $762K | 0.01% |
193,815
| – | – |
|
620
CarMax
KMX
$8.36B
| $760K | 0.01% |
8,490
-3,309
| -28% | -$259K |
|
621
Annaly Capital Management
NLY
$17.4B
| $756K | 0.01% |
28,828
-18,411
| -39% | -$455K |
|
|
CXO
622
DELISTED
CONCHO RESOURCES INC.
CXO
| $750K | 0.01% |
14,557
-64,879
| -82% | -$3.59M |
|
623
Bunge Global
BG
$22.8B
| $749K | 0.01% |
18,201
+717
| +4% | +$27.8K |
|
624
Ally Financial
ALLY
$13.4B
| $742K | 0.01% |
+37,423
| New | +$637K |
|
625
Dr. Reddy's Laboratories
RDY
$9.77B
| $742K | 0.01% |
+70,000
| New | +$712K |
|
Similar funds
PCM
A
MGP
LF
SOMRS
BPA
MIM
Candriam SCA's Q2 2020 Portfolio in Review
As of Q2 2020, Candriam SCA held 903 positions worth $9.47B, up 5% from $9.02B the previous quarter. Its ten largest holdings account for 22% of the portfolio.
Candriam SCA deployed $1.13B of net new capital in Q2 2020, opening 107 new positions and adding to 255 existing holdings. Its largest new stake was JD.com: 744,410 shares worth $44.8M.
By sector, the portfolio is most concentrated in Healthcare at 35% of assets, up from 31% a quarter earlier, followed by Technology and Consumer Discretionary.
On the sell side, the largest reduction was Regeneron Pharmaceuticals, an estimated $103M trimmed.
- Candriam SCA's largest Q2 2020 buy was JD.com: 744,410 shares worth $44.8M.
- Candriam SCA added most to Blueprint Medicines in Q2 2020, an estimated $51.9M increase.
- Candriam SCA's biggest Q2 2020 reduction was Regeneron Pharmaceuticals, cutting an estimated $103M.
- Candriam SCA fully exited Salesforce in Q2 2020, selling an estimated $62.5M.
- Candriam SCA's ten largest holdings make up 22% of its $9.47B portfolio in Q2 2020.
- Candriam SCA opened 107 new positions and closed 103 in Q2 2020.
- Candriam SCA's portfolio value rose 5% quarter-over-quarter to $9.47B.
Based on Candriam SCA's 13F filing for Q2 2020, filed 23 Jul 2020.